К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

Ki-67 on a pathology report: what the percentage means

What Ki-67 means on an IHC report: why there is no single cutoff, which values count as low or high, and when the result actually affects treatment.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026

In short

Ki-67 is a protein found in the nuclei of dividing cells. The percentage on your report shows what share of tumor cells are currently in the cell cycle, which tells you how actively the tumor is growing.

How it appears in your report

  • ‘Ki-67: 15%’ — the share of tumor cells with stained nuclei.
  • ‘Ki-67 proliferation index: 40%’ — the same thing in other words.
  • ‘Ki-67: 25% (hot spot assessment)’ — counted in the most heavily stained areas; the international working group considers this less reproducible than a global assessment across the whole slide.

Ki-67 appears most often in breast cancer reports, but it is reported for other tumors too.

What it means

There is no single cutoff, and the numbers depend on which guideline you look at:

Source Interpretation
RUSSCO low ≤ 20%, high ≥ 30%; 20–30% is weighed against stage, grade and other factors
International Ki67 in Breast Cancer Working Group (IKWG) only ≤ 5% and ≥ 30% are reliable for prognosis, and only in ER+ HER2− cancer, T1–T2, N0–N1

RUSSCO states plainly that Ki-67 should be interpreted in light of the specific lab’s experience. The IKWG advises against basing decisions on Ki-67 between 5% and 30%, because agreement between labs in that range is not good enough.

Does it affect treatment

In breast cancer, Ki-67 together with hormone receptors and HER2 defines the luminal subtype, and the subtype guides which drugs are discussed. But the IKWG stresses that a low Ki-67 is not a reason to skip chemotherapy if the tumor is large or lymph nodes are involved. The decision rests with your treating doctor or tumor board.

Questions to ask your doctor

  • Does the decision about chemotherapy in my case depend on Ki-67?
  • If my value is in the gray zone, do I need a slide review or other tests?
  • What other risk factors are being taken into account?

More in the article on IHC in breast cancer. If your Ki-67 result is unclear, I can go through the report with you.

Sources

  1. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group — JNCI, 2021
  2. Практические рекомендации по лекарственному лечению рака молочной железы — RUSSCO, 2023
  3. Breast Cancer Biomarker Tests — National Cancer Institute, 2025

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles